AI assistant
Replimune Group, Inc. — Director's Dealing 2024
Apr 4, 2024
33193_dirs_2024-04-03_ab3debaa-e528-4a3f-b121-26a9fdc8164b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Replimune Group, Inc. (REPL)
CIK: 0001737953
Period of Report: 2024-04-01
Reporting Person: Xynos Konstantinos (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-04-01 | Common Stock | A | 26665 | — | Acquired | 139379 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-04-01 | Employee Stock Option (right to buy) | $7.73 | A | 80000 | Acquired | 2034-04-01 | Common Stock (80000) | Direct |
Footnotes
F1: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2025 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2028, subject to the Reporting Person's continuous service to the Issuer.
F2: 25% of the shares underlying this stock option vest on April 1, 2025, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.